Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Heluo Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences for the treatment of IgA nephropathy (IgAN). The formula is designed based on the TCM principles of strengthening the spleen (Jianpi) and dredging the collaterals (Heluo), specifically targeting the gut-kidney axis. It is hypothesized to modulate the intestinal microbiota and the mucosal immune system, thereby reducing the production of pathogenic galactose-deficient IgA1 (Gd-IgA1) and inflammatory cytokines. In clinical studies, it is evaluated as an adjunct to standard angiotensin receptor blocker (ARB) therapy to improve clinical outcomes such as proteinuria and hematuria while preserving renal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Heluo Formula.